1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation

Sunscreen Group Remains Cloudy About FDA's Ingredient Evaluations

 
• By Eileen Francis

PASS Coalition fails to find common ground with US FDA as the sunscreen access advocacy group urges significant changes to a draft guidance on safety testing for sunscreen ingredients.

The Public Access to Sunscreens Coalition’s latest attempt to bridge a gap between its idea of adequate information and appropriate procedures for evaluating sunscreen ingredients and FDA's standards and policies does little more than expose the extent of the schism.

The same questions that have tripped up sponsors of sunscreen time-and-extent applications (TEA) for adding ingredients to FDA's OTC sunscreen monograph since Congress passed the industry-backed Sunscreen Innovation Act in 2014 remain unresolved following

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.